Literature DB >> 8471755

Pruritus and cholestasis: therapeutic options.

D A Gillespie1, C R Vickers.   

Abstract

The pathogenesis of pruritus of cholestasis remains unclear. Bile salts do not appear to be the sole prurogens in cholestasis. Histaminergic pathways may be involved, and central opiate receptor processes seem much more important than has previously been recognized. The therapeutic options for relief of cholestatic pruritus are summarized in Table 2. Resins such as cholestyramine are the first line of therapy. In cases where cholestyramine has failed, rifampicin and antihistamines may be beneficial. Opiate antagonists hold great potential if opioid withdrawal-like syndromes can be avoided. Ursodeoxycholic acid and methotrexate have an advantage in not only relieving pruritus but also potentially retarding disease progression in PBC and PSC, respectively, although this remains to be proved. Other agents such as EPO and SAMe remain experimental and require further study to clarify their effectiveness before they can be recommended.

Entities:  

Mesh:

Year:  1993        PMID: 8471755     DOI: 10.1111/j.1440-1746.1993.tb01510.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  7 in total

1.  Pruritus.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-12

2.  The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity.

Authors:  J L Staudinger; B Goodwin; S A Jones; D Hawkins-Brown; K I MacKenzie; A LaTour; Y Liu; C D Klaassen; K K Brown; J Reinhard; T M Willson; B H Koller; S A Kliewer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  Primary sclerosing cholangitis.

Authors:  Joy Worthington; Roger Chapman
Journal:  Orphanet J Rare Dis       Date:  2006-10-24       Impact factor: 4.123

4.  Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.

Authors:  Kenya Kamimura; Takeshi Yokoo; Hiroteru Kamimura; Akira Sakamaki; Satoshi Abe; Atsunori Tsuchiya; Masaaki Takamura; Hirokazu Kawai; Satoshi Yamagiwa; Shuji Terai
Journal:  PLoS One       Date:  2017-06-12       Impact factor: 3.240

5.  Post-Marketing Surveillance Study of the Safety and Efficacy of Nalfurafine (Capsules 2.5 μg, Oral Dispersing Tablets 2.5 μg) in 1186 Patients with Chronic Liver Disease and Intractable Pruritus.

Authors:  Hiroshi Yoshitani; Junko Ito; Hideki Kozono
Journal:  Hepat Med       Date:  2022-05-02

6.  Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease.

Authors:  Tadamichi Kawano; Masanori Atsukawa; Akihito Tsubota; Noritomo Shimada; Hidenori Toyoda; Koichi Takaguchi; Joji Tani; Asahiro Morishita; Atsushi Hiraoka; Shigeru Mikami; Toru Ishikawa; Hironao Okubo; Tsunamasa Watanabe; Tomomi Okubo; Taeang Arai; Korenobu Hayama; Norio Itokawa; Chisa Kondo; Katsuhiko Iwakiri
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.996

7.  Effect of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus on sleep disorders: a study protocol for single-arm, prospective, interventional study.

Authors:  Kazunori Yoh; Hiroki Nishikawa; Hirayuki Enomoto; Yoshinori Iwata; Akio Ishii; Yukihisa Yuri; Noriko Ishii; Yuho Miyamoto; Kunihiro Hasegawa; Chikage Nakano; Ryo Takata; Takashi Nishimura; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  BMJ Open Gastroenterol       Date:  2017-09-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.